New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance.
Bioessays
; 34(8): 681-91, 2012 Aug.
Article
em En
| MEDLINE
| ID: mdl-22674489
ABSTRACT
Growing evidence suggests that pathological overactivation of the endocannabinoid system (ECS) is associated with dyslipidemia, obesity and diabetes. Indeed, this signalling system acting through cannabinoid receptors has been shown to function both centrally and peripherally to regulate feeding behaviour as well as energy expenditure and metabolism. Consequently, modulation of these receptors can promote significant alterations in body weight and associated metabolic profile. Importantly, blocking cannabinoid receptor type 1 function has been found to prevent obesity and metabolic dysfunction in various murine models and in humans. Here we provide a detailed account of the known physiological role of the ECS in energy balance, and explore how recent studies have delivered novel insights into the potential targeting of this system as a therapeutic means for treating obesity and related metabolic disorders.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transdução de Sinais
/
Endocanabinoides
/
Diabetes Mellitus Tipo 2
/
Metabolismo Energético
/
Moduladores de Receptores de Canabinoides
/
Obesidade
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article